Using Tranexamic Acid to Reduce Bleeding During Colon Polyp Removal
Usage of Tranexamic Acid During Colonic Endoscopic Resection Procedures for Reduction Intraprocedural and Postprocedural Bleeding
This study is testing if using tranexamic acid can help reduce bleeding during and after the removal of large colon polyps for patients undergoing this procedure.
Quick facts
| Phase | Phase 4 |
|---|---|
| Study type | Interventional |
| Enrollment | 200 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Assaf-Harofeh Medical Center Government |
| Locations | 1 site (Be’er Ya‘aqov) |
| Trial ID | NCT05345613 on ClinicalTrials.gov |
What this trial studies
This study evaluates the effectiveness of tranexamic acid (TXA) in preventing bleeding during and after endoscopic mucosal resection (EMR) of large colon polyps. The research focuses on patients undergoing this procedure, which, while effective in reducing colon cancer incidence, carries risks of significant bleeding. By administering TXA locally, the investigators aim to minimize both intraprocedural and postprocedural bleeding, potentially improving patient outcomes and reducing the need for additional interventions. The study is being conducted at a tertiary academic center, ensuring a robust patient population and clinical oversight.
Who should consider this trial
Good fit: Ideal candidates include adults over 18 years referred for endoscopic resection of colon lesions.
Not a fit: Patients with a history of allergic reactions to TXA, seizures, or those who are pregnant may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could significantly reduce the incidence of bleeding complications associated with colon polyp removal.
How similar studies have performed: Other studies have shown promising results with TXA in various surgical settings, suggesting potential for success in this novel application.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients referred for endoscopic resection of non-neoplastic and neoplastic lesions in the colon presenting to our tertiary academic center. * Age \> 18 years Exclusion Criteria: * patients with histories of allergic reactions to TXA * history of seizures * pregnancy
Where this trial is running
Be’er Ya‘aqov
- Shamir Medical Center — Be’er Ya‘aqov, Israel (Recruiting)
Study contacts
- Principal investigator: Anton Bermont, MD — Assaf-Harofeh Medical Center
- Study coordinator: Anton Bermont, MD
- Email: bermont@doctor.com
- Phone: +972526944145
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.